Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $10.1M | $4.91M | $0.00 |
| Revenue growth | — | — | — | — | — | -51.3% | -100.0% |
| Operating income | -$13.1M | -$29.4M | -$42.1M | -$47.3M | -$52.0M | -$56.2M | -$36.5M |
| Operating margin | — | — | — | — | -515.3% | -1143.4% | — |
| Net income | -$13.1M | -$29.5M | -$42.3M | -$46.2M | -$47.9M | -$53.0M | -$39.0M |
| Net margin | — | — | — | — | -475.0% | -1079.9% | — |
| EPS (diluted) | -$17.12 | -$4.93 | -$1.81 | -$1.96 | -$1.24 | -$96.40 | -$50.83 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.6M | -$27.5M | -$35.9M | -$41.7M | -$33.3M | -$56.0M | -$33.3M |
| Capital expenditures | $4.00K | $74.0K | $93.0K | $8.00K | $7.00K | $0.00 | — |
| Free cash flow | -$12.6M | -$27.6M | -$36.0M | -$41.7M | -$33.3M | -$56.0M | — |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.92M | $157M | $42.7M | $24.5M | $96.3M | $38.8M | $48.9M |
| Total assets | $4.69M | $163M | $126M | $85.6M | $104M | $45.2M | $53.0M |
| Total liabilities | $7.52M | $13.5M | $15.1M | $17.2M | $27.4M | $16.4M | $10.5M |
| Long-term debt | $3.19M | $1.92M | $4.88M | $3.29M | $1.72M | $124K | $0.00 |
| Shareholders' equity | -$30.6M | $149M | $111M | $68.5M | $76.5M | $28.8M | $42.5M |
| Retained earnings | -$31.3M | -$60.8M | -$103M | -$149M | -$197M | -$250M | -$289M |
| Shares (wtd avg diluted) | 764K | 23.3M | 23.4M | 23.5M | 38.5M | 550K | 767K |
Every figure is extracted from SPRUCE BIOSCIENCES, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.